Pharma Major Lupin announced today that it has received final approval for its Vancomycin Hydrochloride Capsules, 125 mg and 250 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals Vancocin capsules, 125 mg and 250 mg strengths.

Lupin Pharmaceuticals (LPI), the company's US subsidiary would commence marketing the product shortly. Lupin's Vancomycin capsules 125 mg and 250 mg are the AB rated generic equivalent of ANI Pharmaceuticals Vancocin capsules and are indicated for the treatment of C. difficile-associated diarrhea and also for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
 
Vancocin Capsules had annual US sales of USD 164.2 million (IMS MAT September, 2014).

Shares of the company declined Rs 33.55, or 2.12%, to settle at Rs 1,550.80. The total volume of shares traded was 61,265 at the BSE (Monday).